Teva Pharmaceutical Industries Ltd. will end human testing of fremanezumab as a treatment for chronic cluster headache after an analysis determined that the study was unlikely to meet its main goal.

Testing of the drug as a therapy for episodic cluster headaches will continue, the Israeli drugmaker said in a June 15 statement. Fremanezumab is under review by U.S. and EU regulators as a quarterly or monthly injection for the prevention of migraines in adults.

"While we are disappointed with this outcome, we remain optimistic that fremanezumab could have clinical benefits in additional conditions, beyond migraine," Tushar Shah, senior vice president and head of global specialty clinical development at Teva, said in the statement.

Fremanezumab belongs to a group of medicines known as calcitonin gene-related peptide, or CGRP, inhibitors. The group includes Eli Lilly and Co.'s galcanezumab and Amgen Inc. and Novartis AG's Aimovig, which won U.S. approval in May.